Header Logo

Connection

JOSEPH JANKOVIC to Dopamine

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Dopamine.
JOSEPH JANKOVIC
Connection Strength
2.293
Dopamine
  1. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
    View in: PubMed
    Score: 0.475
  2. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct; 77(1-2):128-38.
    View in: PubMed
    Score: 0.220
  3. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002 Feb 12; 58(3):341-6.
    View in: PubMed
    Score: 0.170
  4. Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
    View in: PubMed
    Score: 0.152
  5. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
    View in: PubMed
    Score: 0.108
  6. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183.
    View in: PubMed
    Score: 0.089
  7. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012 Sep; 11(6):768-73.
    View in: PubMed
    Score: 0.088
  8. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009 Feb; 15(1):28-35.
    View in: PubMed
    Score: 0.068
  9. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008 Jul 30; 1222:222-9.
    View in: PubMed
    Score: 0.066
  10. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008 Jun; 105(5):1970-8.
    View in: PubMed
    Score: 0.065
  11. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007 Dec; 21(14):3835-44.
    View in: PubMed
    Score: 0.062
  12. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
    View in: PubMed
    Score: 0.058
  13. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005 Dec 02; 337(4):1133-8.
    View in: PubMed
    Score: 0.055
  14. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005 Mar 29; 377(2):106-9.
    View in: PubMed
    Score: 0.053
  15. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005 Jan; 191(1):154-62.
    View in: PubMed
    Score: 0.052
  16. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004 Oct 26; 63(8):1541-2; author reply 1541-2.
    View in: PubMed
    Score: 0.051
  17. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
    View in: PubMed
    Score: 0.049
  18. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
    View in: PubMed
    Score: 0.049
  19. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004; 94:275-86.
    View in: PubMed
    Score: 0.049
  20. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003 Jan 17; 72(9):1073-83.
    View in: PubMed
    Score: 0.045
  21. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
    View in: PubMed
    Score: 0.037
  22. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999 Nov; 73(5):2218-21.
    View in: PubMed
    Score: 0.036
  23. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999 Oct; 159(2):451-8.
    View in: PubMed
    Score: 0.036
  24. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
    View in: PubMed
    Score: 0.035
  25. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999; 64(15):1275-85.
    View in: PubMed
    Score: 0.034
  26. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010 Oct; 115(1):188-99.
    View in: PubMed
    Score: 0.019
  27. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010 Feb; 37(2):307-13.
    View in: PubMed
    Score: 0.018
  28. Parkinson's disease: recent advances in therapy. South Med J. 1988 Aug; 81(8):1021-7.
    View in: PubMed
    Score: 0.017
  29. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.014
  30. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003 Sep; 86(6):1338-45.
    View in: PubMed
    Score: 0.012
  31. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm (Vienna). 2000; 107(10):1165-73.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.